Today: 22 March 2026
Browse Category

NASDAQ:PRGN 22 August 2025

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

The FDA approved Ionis’s Dawnzera for hereditary angioedema and Precigen’s Papzimeos for recurrent respiratory papillomatosis, marking a first for viral immunotherapy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million. Johnson & Johnson announced a $2 billion biomanufacturing facility in North Carolina. Apollo Hospitals’ managing director sold a $170 million stake in a major block trade.

Stock Market Today

  • Tenaz Energy (TSX:TNZ) Valuation Under Spotlight After Profit Turnaround
    March 22, 2026, 12:11 PM EDT. Tenaz Energy (TSX:TNZ) posted a net income of CA$315.61 million in 2025, recovering from prior losses, with sharp production gains driving a 49.35% one-month and 158.57% year-to-date share price surge. Despite these gains, its price-to-earnings (P/E) ratio stands at a modest 6.9, below the Canadian Oil and Gas sector average of 18.8. Revenue forecasts suggest 25.6% annual growth, but earnings are projected to decline 41.2% annually over three years, raising questions about sustained valuation gaps. A discounted cash flow (DCF) model estimates intrinsic value at CA$358.16 per share, far above the current CA$67.85 price, highlighting a potential mispricing. Investors must balance the optimistic turnaround with risks including heavy revenue dependence on the Netherlands and declining future earnings.
Go toTop